Day Trade Watchlist:
OTIV , TKMR , HLF SLXP , SUPN, TQNT, ASNA , MBLY, XIV , TSLA MBLY, XIV, ABBV, MDT, MNGA, NXTD, RWLK, BABA, OTIV, UVXY, OPK, CCL, NUGT
News that matter:
Russian miner MTL is lower by another 30% this morning on continued
bankruptcy concerns. MTL is currently indicated at $0.71/share. The stock
lost 35% in Moscow trading today (MTL)
ABnote, Employing the oti WAVE Device, Launches Major NFC Electronic
Payment Pilot With Leading North American Financial Institution (OTIV)
ReWalk announces reimbursement coverage by
major German insurance company (RWLK)
Doral Fincl said yesterday after the close
that they 'remain confident in the rule of law and that it will prevail' as DRL
vs. Hacienda trial concluded (DRL)
JP Energy Partners (NYSE: JPEP) commenced its
IPO of 13.75 mln common units representing limited partner interests
OM Asset Mgmt (NYSE: OMAM) announces launch
of an IPO of 22 mln shares, or 18.3%, of its ordinary shares
Tekmira Pharma is collaborating with an
international consortium to provide an RNAi based investigational therapeutic
for expedited clinical studies in West Africa; consortium receives GBP3.2 mln
funding from Wellcome Trust (TKMR)
Ideal Power (IPWR) has received
purchase orders for six of its 30kW battery converters for use in two 100kW
wind turbine installations. Installation of these units is expected to be
complete in early 2015. (IPWR)
Misonix (MSON) announced that it
has supported the Uganda Spine Surgery Mission by providing an ultrasonic
BoneScalpel for use in a number of advanced spinal surgeries. (MSON)
Cancer Genetics (CGIX) and Beth Israel
Deaconess Medical Center have entered into a collaboration to examine genomic
biomarkers in patients with Diffuse Large B-Cell Lymphoma, and use an
integrated approach to investigate their association with patient outcome.
Titan Pharma (TTNP) announced that
patient enrollment in the Phase 3 study of Probuphine, the co's investigational
subdermal implant for the maintenance treatment of opioid dependence, has
reached the halfway mark. Co's partner, Braeburn Pharma, is sponsoring the
study and expects it to be fully enrolled before the end of this year, with
study completion on schedule by the middle of 2015. (TITN)
No comments:
Post a Comment